Thor Medical ASA Total Assets
Thor Medical ASA total assets. Based on the latest financial reports, Thor Medical ASA (TRMED) holds total assets worth Nkr724.10 Million NOK (≈ $76.20 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Thor Medical ASA for the company's overall valuation and market capitalisation.
Total Assets of Thor Medical ASA (2020–2025)
Total assets of Thor Medical ASA from 2020 to 2025. This chart illustrates how Thor Medical ASA's total assets have evolved over time, based on quarterly financial data. See latest Thor Medical ASA stock price today for real-time trading data and today's change.
Thor Medical ASA - Asset Composition Analysis
Thor Medical ASA Total Assets Breakdown (December 2025)
Thor Medical ASA total assets breakdown as of December 2025. Thor Medical ASA's total assets of Nkr724.10 Million consist of 28.2% current assets and 71.9% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 25.3% |
| Accounts Receivable | Nkr295.00K | 0.0% |
| Inventory | Nkr2.96 Million | 0.4% |
| Property, Plant & Equipment | Nkr244.23 Million | 34.5% |
| Intangible Assets | Nkr226.93 Million | 32.0% |
| Goodwill | Nkr37.22 Million | 5.3% |
Asset Composition Trend (2020–2025)
This chart illustrates how Thor Medical ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Thor Medical ASA (TRMED) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Thor Medical ASA's current assets represent 28.2% of total assets in 2025, a decrease from 98.2% in 2020.
- Cash Position: Cash and equivalents constituted 25.3% of total assets in 2025, down from 93.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 37.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is property, plant & equipment at 34.5% of total assets.
Thor Medical ASA Competitors by Total Assets
Key competitors of Thor Medical ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
3SBio Inc
F:83B
|
Germany | €36.25 Billion |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥28.15 Billion |
Thor Medical ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.89 | 8.87 | 3.63 |
| Quick Ratio | 1.85 | 8.78 | 3.63 |
| Cash Ratio | 0.00 | 8.01 | 3.43 |
| Working Capital | Nkr77.00 Million | Nkr220.40 Million | Nkr272.63 Million |
Thor Medical ASA - Advanced Valuation Insights
This section examines the relationship between Thor Medical ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.23 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | 71.0% |
| Total Assets | Nkr708.64 Million |
| Market Capitalization | $182.95 Million USD |
Valuation Analysis
Below Book Valuation: The market values Thor Medical ASA's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Thor Medical ASA's assets grew by 71.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Thor Medical ASA (2020–2025)
The table below shows the annual total assets of Thor Medical ASA from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr708.64 Million ≈ $74.57 Million |
+71.00% |
| 2024-12-31 | Nkr414.40 Million ≈ $43.61 Million |
+25.26% |
| 2023-12-31 | Nkr330.83 Million ≈ $34.81 Million |
+201.73% |
| 2022-12-31 | Nkr109.64 Million ≈ $11.54 Million |
-63.04% |
| 2021-12-31 | Nkr296.67 Million ≈ $31.22 Million |
-5.70% |
| 2020-12-31 | Nkr314.61 Million ≈ $33.11 Million |
-- |
About Thor Medical ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It offers thorium-228, as well as radium-224 and lead-212 to radiopharmaceutical customers. The company was incorporated in 2009 and is headquartered in Oslo, Norway.